Design and Development of Analogues of beta-Alanine as Therapeutics for AD
Aperçu du projet
When brain cells are injured during Alzheimer’s disease, those cells may either die or become too electrically excitable.
This study’s objective is to design drugs that prevent harmful levels of electrical excitability in brain cells.
The expected outcome of is to discover a prototype new drug for Alzheimer’s disease. This drug will target a new concept: that brain electrical hyperexcitability causes disease progression.
Donald Weaver , University Health Network
Partenaire et Donateurs
Alzheimer Society of Canada